Piramal Group Overview

  • Founded
  • 1947
Founded
  • Status
  • Public
  • Employees
  • 6,638
Employees
  • Stock Symbol
  • 500302
Stock Symbol
  • Investments
  • 42
  • Share Price
  • $34.61
  • (As of Wednesday Closing)

Piramal Group General Information

Description

Piramal Enterprises Ltd is a diversified holdings company that functions through two segments: financial services and pharma. Its financial-services business focuses on lending, primarily to real estate developers. Alternative asset management and retail financing operations fall into this segment, as well. Pharma is divided into three businesses: Contract Development and Manufacturing, providing solutions across drug lifecycle; Complex Hospital Generics provides anesthesia and antibiotic products; and Consumer Healthcare, providing self-care products. The pharma segment focuses on the manufacture, development, and supply of pharmaceuticals for hospitals worldwide.

Contact Information

Website
www.piramal.com
Formerly Known As
Nicholas Piramal India Limited
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Stock Exchange
BOM
Primary Office
  • Agastya Corporate Park, Opposite Fire Brigade
  • Kamani Junction, LBS Marg, Kurla (West)
  • Mumbai, Maharashtra 400070
  • India
+91 022 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Piramal Group Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$34.61 $34.63 $17.87 - $40.29 $8.27B 239M 27K $0.67

Piramal Group Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019
EV 12,471,900 8,343,986 6,948,869 12,298,524
Revenue 1,707,774 1,721,689 1,839,296 1,697,693
EBITDA 1,016,447 1,083,922 980,592 986,978
Net Income 158,376 179,078 3,382 209,602
Total Assets 14,178,016 10,500,105 9,932,190 12,327,480
Total Debt 8,336,248 5,385,884 5,600,398 8,069,477
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Piramal Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Piramal Group‘s full profile, request access.

Request a free trial

Piramal Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Piramal Enterprises Ltd is a diversified holdings company that functions through two segments: financial services and ph
Pharmaceuticals
Mumbai, India
6,638 As of 2021
00000
0000 00000

00. 0000

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in
000000000000000
Hyderabad, India
00000 As of 0000
00000
00000000000 00000

000 0000

iquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
000000000000000
Mumbai, India
00000 As of 0000
00.00 0000-00-00
00000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Piramal Group Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dr. Reddy's Laboratories Corporation Hyderabad, India 00000 00000 00000000000 00000
000 00000000000000 Corporation Mumbai, India 00000 00000000000
You’re viewing 2 of 2 competitors. Get the full list »

Piramal Group Patents

Piramal Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3768659-A1 An improved asymmetric synthesis of alpha-(diarylmethyl) alkyl amines Pending 21-Mar-2018 0000000000
JP-2021523092-A Improved asymmetric synthesis of alpha- (diarylmethyl) alkylamines Pending 21-Mar-2018 0000000000
US-20210061752-A1 An improved asymmetric synthesis of alpha-(diarylmethyl) alkyl amines Pending 21-Mar-2018 0000000000
US-20180354977-A1 A process for preparation of fosaprepitant dimeglumine and an intermediate thereof Granted 01-Dec-2015 00000000000
US-10428097-B2 Process for preparation of fosaprepitant dimeglumine and an intermediate thereof Active 01-Dec-2015 C07F9/65583
To view Piramal Group’s complete patent history, request access »

Piramal Group Executive Team (22)

Name Title Board Seat Contact Info
Kalpesh Kikani Chief Executive Officer
Vikram Bector President & Chief Human Resources Officer
Viral Gandhi President & Group Chief Information Officer
Jatin Lal President, Mergers & Acquisitions
Rajesh Laddha Chief Financial Officer, Finance & Board Member
You’re viewing 5 of 22 executive team members. Get the full list »

Piramal Group Board Members (15)

Name Representing Role Since
0000 0000000 Piramal Group Chairman & Board Member 000 0000
000000 0000000000 Self Board Member 000 0000
000000 00000000 Self Board Member 000 0000
0000000 0000000 Piramal Group Chairman & Board Member 000 0000
000000000 000000 Piramal Group Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Piramal Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Piramal Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Piramal Group‘s full profile, request access.

Request a free trial

Piramal Group Investments & Acquisitions (42)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 29-Sep-2021 0000000000 00.000 Specialized Finance 0000 0000
00000000000 0 25-Feb-2021 0000000000 00.000 Specialty Chemicals
0&0 000000000 01-Sep-2020 000000000 000.00 Buildings and Property 00000 000
0000000 05-Jun-2018 0000000000 Pharmaceuticals
Shreya Lifesciences (Digeplex and associated brands) 30-Nov-2017 Corporate Asset Purchase Buildings and Property 0000000 0
You’re viewing 5 of 42 investments and acquisitions. Get the full list »

Piramal Group Subsidiaries (5)

Company Name Industry Location Founded
Pel Healthcare Pharmaceuticals Sellersville, PA 2020
00000000000 000000 Specialty Chemicals Dahej, India 0000
00000000 Pharmaceuticals Saint Paul, MN 0000
00000 0000000 0000 Specialized Finance Mumbai, India 0000
000000'0 Personal Products Mumbai, India 0000
To view Piramal Group’s complete subsidiaries history, request access »

Piramal Group Exits (12)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 23-Aug-2016 000000000 000.00 Completed
  • 0000000 00000
0000 0000 12-Jul-2016 000000000 Completed
  • 2 buyers
00000 00000 000000 29-Mar-2016 00 000000000000000 00000 Completed
  • 2 buyers
000000 0000000000 17-Apr-2015 00000 00000 00 0000 Completed
  • 0000000 00000
Piramal Glass 28-Jul-2014 Merger/Acquisition Completed
You’re viewing 5 of 12 exits. Get the full list »